SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (978)1/26/2000 4:20:00 PM
From: Rick Strange  Read Replies (1) of 1386
 
I, for one, admit that I have preached to the choir. I do, indeed, understand your comments and I think that your point of view is objective and that a traditional stance will be maintained regarding Hu-211 trial structure and that you will be proven correct.

But, I do believe that the FDA can be made to change. One has only to look at how flexible they have been when considering AIDS drugs and fast tracking their approval. And this is good.

Would that it were that the same logic was applied toward less politically correct killers as TBI. If the logic for fast tracking approval of AIDS drugs is valid, I think it is, would it not also be valid in any situation where there is no known alternative.

Saving lives and enhancing the quality of life should be a universal goal at the FDA and not up to an individual department head and defer to his style of conducting the approval process. Again, I step down off of my soap box.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News